MYC-induced myeloid leukemogenesis is accelerated by all six members of the antiapoptotic BCL family

Oncogene

Volumn 28, Issue 9, 2009, Pages 1274-1279

  Beverly, L J ^a   Varmus, H E ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

BCL2; BCLb; BCLw; BCLxl; BFL1; MCL1

Indexed keywords

B CELL LYMPHOMA PROTEIN; BCL2 RELATED PROTEIN A1; CD11B ANTIGEN; CELL SURFACE MARKER; HISTONE H3; KI 67 ANTIGEN; MYC PROTEIN; ONCOPROTEIN; PROTEIN BCL 10; PROTEIN BCL 2; PROTEIN BCL B; PROTEIN BCL W; PROTEIN BCL XL; PROTEIN GR 1; PROTEIN MCL 1; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE MARROW; BREAST TUMOR; CANCER CELL; CANCER INFILTRATION; CELL DEATH; CELL PROLIFERATION; COLON TUMOR; CONTROLLED STUDY; GENE EXPRESSION; GENE OVEREXPRESSION; HEPATOMEGALY; HUMAN; HUMAN CELL; LEUKEMIA CELL; LEUKEMOGENESIS; LIVER TUMOR; LUNG TUMOR; LYMPH NODE; LYMPHOMA CELL; MOUSE; NONHUMAN; OVARY TUMOR; PRIORITY JOURNAL; PROSTATE TUMOR; SPLEEN; SPLENOMEGALY; THYMUS;

APOPTOSIS; GENES, MYC; HUMANS; LEUKEMIA, MYELOID; ONCOGENE PROTEINS;

EID: 62049084053     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2008.466     Document Type: Article

References (26)

1. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG et al. (2005). Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 17: 393-403.
2. Chen S, Dai Y, Harada H, Dent P, Grant S. (2007). Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res 67: 782-791.
3. Cory S, Huang DC, Adams JM. (2003). The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 22: 8590-8607.
4. Cosulich SC, Worrall V, Hedge PJ, Green S, Clarke PR. (1997). Regulation of apoptosis by BH3 domains in a cell-free system. Curr Biol 7: 913-920.
5. Hemann MT, Bric A, Teruya-Feldstein J, Herbst A, Nilsson JA, Cordon-Cardo C et al. (2005). Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature 436: 807-811.
6. Holinger EP, Chittenden T, Lutz RJ. (1999). Bak BH3 peptides antagonize Bcl-xL function and induce apoptosis through cytochrome c-independent activation of caspases. J Biol Chem 274: 13298-13304.
7. Horvitz HR. (1999). Genetic control of programmed cell death in the nematode Caenorhabditis elegans. Cancer Res 59: 1701s-1706s.
8. Kawasaki T, Yokoi S, Tsuda H, Izumi H, Kozaki K, Aida S et al. (2007). BCL2L2 is a probable target for novel 14q11.2 amplification detected in a non-small cell lung cancer cell line. Cancer Sci 98: 1070-1077.
9. Kohl TM, Hellinger C, Ahmed F, Buske C, Hiddemann W, Bohlander SK et al. (2007). BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts. Leukemia 21: 1763-1772.
10. Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S et al. (2006). Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 10: 375-388.
11. Lanave C, Santamaria M, Saccone C. (2004). Comparative genomics: the evolutionary history of the Bcl-2 family. Gene 333: 71-79.
12. Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H et al. (2007). Clustal W and Clustal X version 2.0. Bioinformatics 23: 2947-2948.
13. Letai A, Sorcinelli MD, Beard C, Korsmeyer SJ. (2004). Antiapoptotic BCL-2 is required for maintenance of a model leukemia. Cancer Cell 6: 241-249.
14. Luo H, Li Q, O'Neal J, Kreisel F, Le Beau MM, Tomasson MH. (2005). c-Myc rapidly induces acute myeloid leukemia in mice without evidence of lymphoma-associated antiapoptotic mutations. Blood 106: 2452-2461.
15. Mandal M, Borowski C, Palomero T, Ferrando AA, Oberdoerffer P, Meng F et al. (2005). The BCL2A1 gene as a pre-T cell receptor-induced regulator of thymocyte survival. J Exp Med 201: 603-614.
16. Reed JC. (2006). Drug insight: cancer therapy strategies based on restoration of endogenous cell death mechanisms. Nat clin pract Oncol 3: 388-398.
17. Riedl SJ, Salvesen GS. (2007). The apoptosome: signalling platform of cell death. Nat Rev Mol Cell Biol 8: 405-413.
18. Schultz J, Milpetz F, Bork P, Ponting CP. (1998). SMART, a simple modular architecture research tool: identification of signaling domains. Proc Natl Acad Sci USA 95: 5857-5864.
19. Shoemaker AR, Mitten MJ, Adickes J, Ackler S, Refici M, Ferguson D et al. (2008). Activity of the Bcl-2 family inhibitor ABT-263in a panel of small cell lung cancer xenograft models. Clin Cancer Res 14: 3268-3277.
20. Swanson PJ, Kuslak SL, Fang W, Tze L, Gaffney P, Selby S et al. (2004). Fatal acute lymphoblastic leukemia in mice transgenic for B cell-restricted bcl-xL and c-myc. J Immunol 172: 6684-6691.
21. Valdez BC, Murray D, Ramdas L, de Lima M, Jones R, Kornblau S et al. (2008). Altered gene expression in busulfan-resistant human myeloid leukemia. Leuk Res 32: 1684-1697.
22. Vaux DL, Cory S, Adams JM. (1988). Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335: 440-442.
23. Wesarg E, Hoffarth S, Wiewrodt R, Kröll M, Biesterfeld S, Huber C et al. (2007). Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer. Int J Cancer 121: 2387-2394.
24. Yasui K, Mihara S, Zhao C, Okamoto H, Saito-Ohara F, Tomida A et al. (2004). Alteration in copy numbers of genes as a mechanism for acquired drug resistance. Cancer Res 64: 1403-1410.
25. Youle RJ, Strasser A. (2008). The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9: 47-59.
26. Zhai D, Jin C, Satterthwait AC, Reed JC. (2006). Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins. Cell Death Differ 13: 1419-1421.